# Amgen (AMGN) — News AMGN · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/amgn/news ## Recent headlines - [Dow Jones unofficially closes up 189.88 points, or 0.37%, at 51,844.83](https://www.ainvest.com/news/dow-jones-unofficially-closes-189-88-points-0-37-51-844-83-2610) — AInvest Wire, Oct 12, 2026 The Dow Jones Industrial Average (DJIA) rose 189.88 points, or 0.37%, to close at 51,844.83 on Friday, reflecting modest gains amid ongoing market adjustments. The index, which tracks the performance of 30 large, publicly traded U.S. companies, has undergone recent changes to its composition, with… - [Amgen Inc: Guggenheim cuts target price to $378 from $388](https://www.ainvest.com/news/amgen-guggenheim-cuts-target-price-378-388-2610) — AInvest Wire, Oct 12, 2026 Guggenheim Securities has revised its price target for Amgen Inc (AMGN), reducing it to $378 from a previous level of $388, according to recent analyst updates. The adjustment reflects a reassessment of the biopharmaceutical company’s near-term outlook, though the firm has not indicated a change in… - [Gen Ilac - Granted exclusive rights for registration, sales, marketing, and distribution](https://www.ainvest.com/news/gen-ilac-granted-exclusive-rights-registration-sales-marketing-distribution-2610) — AInvest Wire, Oct 12, 2026 Gen Ilac, a pharmaceutical company, has recently been granted exclusive rights for the registration, sales, marketing, and distribution of a product, marking a strategic development in its business operations. This move aligns with broader industry trends where companies seek to expand their market… - [Amgen Inc: UBS raises target price to $470 from $430](https://www.ainvest.com/news/amgen-ubs-raises-target-price-470-430-2610) — AInvest Wire, Oct 9, 2026 UBS has revised its price target for Amgen Inc (AMGN), raising it to $470 from $430, reflecting a positive reassessment of the company’s outlook [1]. The adjustment follows recent developments in Amgen’s portfolio and market positioning. Analysts at UBS highlighted the company’s progress in key… - [Bio-pharmaceutical stocks fell in intraday trading, with Eli Lilly down 4.73%, Amgen falling 2.93% and Merck sliding 2.33%.](https://www.ainvest.com/news/bio-pharmaceutical-stocks-fell-intraday-trading-eli-lilly-4-73-amgen-falling-2-93-merck-sliding-2-33-2610-74) — AInvest Wire, Oct 8, 2026 Bio-pharmaceutical stocks experienced a decline in intraday trading on Monday, with several major players posting notable losses. Eli Lilly shares dropped 4.73%, while Amgen fell 2.93%. Merck also saw a decline, with its stock sliding 2.33% . The downward movement reflects broader market volatility… ## Similar Stocks - [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock - [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock - [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock - [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new) - [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares - [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock - [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock - [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock - [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock - [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).